AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$GH

Talasaz AmirAli sold $6.3M of GH (indirect holdings)

Talasaz AmirAli (Co-Chief Executive Officer) sold 37,500 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $169.16 ($168.20–$170.29, $6.34M total) across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Talasaz AmirAli
Published Aug 24, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for Guardant Health.

02

Market read

First public disclosure of a sizable insider sale by Guardant Health's co‑CEO.

03

What to watch

Potential upcoming clinical data releases may offset any negative sentiment from the sale.

Relevance 6/10Novelty 7/10Timing: filed 2026-08-24, reflects same‑day insider activity

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Co-CEO Talasaz AmirAli sold 37,500 shares for $6.34M via open-market transactions on 2026-08-21.

Expected impact

Potential slight dip in GH price over the next few days.

Evidence & confidence

Insider sales by a top executive can be viewed as a negative signal, but the amount ($6.3M) is not material for a mid‑cap biotech.

Market effects

Sector

Minimal impact on broader biotech sector; similar insider sales are common.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Company
    Guardant Health, Inc.

    Biotech firm focused on liquid biopsy diagnostics.

  • Executive
    Talasaz AmirAli

    Co-Chief Executive Officer of Guardant Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GH insider trading history →

Related articles

OCT 20
$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

insidermonkey.com3 min
OCT 9
$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.

onclive.com6 min